What type of anti-cancer targeted drug is Asiminib?

Asciminib (Asciminib) is a new type of anti-cancer targeted drug, which is a tyrosine kinase inhibitor (TKI). Its main role is to treat chronic myelogenous leukemia (CML) and other hematological malignancies caused by BCR-ABL1 mutations by selectively inhibiting the tyrosine kinase activity produced by the BCR-ABL1 fusion gene. Different from traditional tyrosine kinase inhibitors (such as imatinib, dasatinib, etc.), aximinib has unique advantages in overcoming some common resistance mutations by specifically targeting the binding site of BCR-ABL1 tyrosine kinase.

The target of Asiminib is mainlyBCR-ABL1 fusion protein, which is the most common causative factor of chronic myelogenous leukemia (CML). The drug specifically binds to the binding site with structural changes of BCR-ABL1 protein, inhibits its tyrosine kinase activity and prevents the proliferation of tumor cells. Unlike traditional TKIs, Aceminib is designed to avoid the ATP binding sites of traditional drugs, thus being able to effectively overcome some traditional TKIResistance mutations that cannot be treated by drugs, especially T315I mutated CML patients.

Asiminib is approved to treat adult patients with chronic myelogenous leukemia (CML) who are resistant or intolerant to imatinib. Its unique mechanism allows the drug to have certain efficacy against a variety of BCR-ABL1 mutations, including T315I mutations, which provides a new treatment option for patients who fail traditional TKI treatments. Drugs are usually well tolerated during treatment and can significantly reduce the patient's leukemia cell load and improve clinical symptoms.

Although Asiminib has good drug resistance and efficacy, patients still need to use it under the guidance of professional doctors and conduct relevant examinations regularly, such as blood routine and liver function. The side effects of aceminib are relatively mild, and common ones include mild anemia, leukopenia, abnormal liver function, etc., but these side effects are controllable in most patients. Overall, aximini provides a new treatment option for patients with chronic myelogenous leukemia, especially those who are resistant to other TKIs.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib